SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

Regeneron’s Libtayo Dosing Application Under FDA Review

A U.S. supplemental biologics license application for Libtayo dosing is under review, with a decision expected in March 2027.

REGN

Related stories